Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus

Lupus

Volumn 14, Issue 10, 2005, Pages 856-858

  Mak, Anselm ^a   Mok, C C ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Haematological; Haemolysis; Immunosuppressive; Mycophenolic acid; Transplant

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEMOLYTIC ANEMIA; HUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANEMIA, HEMOLYTIC; ANEMIA, REFRACTORY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 27744462578     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2163cr     Document Type: Review

References (21)

1. Mok CC, Lee KW, Ho CTK et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 2000; 39: 399-406.
2. Massardo L, Martinez M, Jacobelli S. Survival of Chilean patients with systemic lupus erythematosus. Semin Arthritis Rheum 1994; 24: 1-11.
3. Kokori SI, Ioannidis JP, Voulgarelis M et al. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am J Med 2000; 108: 198-204.
4. Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001; 10: 152-153.
5. Asano Y, Maeda M, Uchida N et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 2001; 80: 634-638.
6. Flores G, Cunningham-Rundles C, Newland AC et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993; 44: 237-242.
7. Perrotta S, Locatelli F, La Manna A et al. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002; 116: 465-467.
8. Mok CC, Lai KN. Mycophenolate mofetil in lupus nephritis. Am J Kidney Dis 2002; 40: 447-457.
9. Avina-Zubieta JA, Galindo-Rodriguez G, Robledo I et al. Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus. Lupus 2003; 12: 52-57.
10. Rivero SJ, Alger M, Alarcon-Segovia D. Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal. Arch Intern Med 1979; 139: 773-776.
11. Zimmer-Molsberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anaemia. Lancet 1997; 350: 1003-1004.
12. Howard J, Hoffbrand AV, Prentice HG et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002; 117: 712-715.
13. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
14. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004; 43: 377-380.
15. Alba P, Karim MY, Hunt BJ et al. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003; 12: 633-635.
16. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003; 12: 630-632.
17. Karim MY, Alba P, Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-882.
18. Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1508-1512.
19. Fossati-Jimack L, Ioan-Facsinay A, Reininger L et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J Exp Med 2000; 191: 1293-1302.
20. Jonsson CA, Carlsten H. Mycophenolic acid inhibits inosine 5′-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells. Int Immunopharmacol 2003; 3: 31-37.
21. Ramos MA, Pinera C, Setien MA et al. Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice. Nephrol Dial Transplant 2003; 18: 878-883.